Erectile Dysfunction Drug Companies
to Benefit from Largely Untapped Markets in Europe
20 September, 2005
Even with 30 million cases of erectile
dysfunction (ED) registered in Europe, the infertility drugs
market has not taken off to the expected extent in the region. The
blame could lie largely with the conservative attitude regarding
infertility among its people. While more than half of the men over
40 years of age suffer from this disorder, only 10 to 15 per cent
seek treatment.
Drug companies can profit from these untapped markets
by improving awareness in the target population. More men have already
started consulting doctors, especially since ED is treatable at
any stage.
There is also a high prevalence of ED in comorbid
medical conditions and through associated risk factors such as cardiovascular
diseases, hypertension, dyslipidemia
and depression. Superior R&D and innovation-focused strategies
will enable market participants to better harness the potential
of this market.
Companies have to focus on product innovation and
competitive pricing for better targeting of consumers and brand
positioning. They should consider generic product development strategies
to sustain their reputation in this field.
To know more read:
http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/09-20-2005/0004110861&EDATE=
